Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

18.45 +0.01 (+0.05%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries ADR

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
Amid the election, and a Fed rate vote, earnings season roars ahead. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Statement on European Commission Decision; Company to Appeal
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today
Via Benzinga
A Closer Look at 4 Analyst Recommendations For Teva Pharmaceutical Indus
Via Benzinga
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,400 Today
Via Benzinga
Key Takeaways From Teva Pharmaceutical Indus Analyst Ratings
Via Benzinga
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes
Teva Pharmaceuticals will pay $450 million to resolve allegations of kickback schemes involving Medicare copays and price-fixing. This settlement is part of a broader crackdown on healthcare fraud... 
Via Benzinga
Topics Fraud
Exposures Legal
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
Via Benzinga
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026. 
Via Benzinga
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
From Teva Pharmaceutical Industries Ltd; mAbxience
Via GlobeNewswire
Teva Launches Generic Version Of Sandostatin In The US
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are down Tuesday. Here's what you need to know. 
Via Benzinga
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
$1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the... 
Via Benzinga
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva to Present at the Bank of America 2024 Global Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. 
Via Benzinga
Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies
Baltimore secures an $80 million settlement with Teva Pharmaceuticals in its opioid crisis litigation. Funds will be allocated to education, recovery centers, and outreach initiatives. 
Via Benzinga
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
Via Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.